BEIJING, November 11, 2011 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) ("Lotus" or the "Company"), a profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), today announced its financial results for the third fiscal quarter ended September 30, 2011. Summary financial data is provided below:
Third Quarter 2011 Financial Highlights
Chairman and Chief Executive Officer Mr. Zhongyi Liu stated, "As we focused our efforts on the construction of our headquarter facility in 2011, there were some major changes on the competitive landscape for our business, which put significant pressure on our gross margins. Retail sales continue to deliver solid results with 27.4% growth in revenue versus the same period in 2010, driven primarily by our Over-the-Counter division's continued growth. Construction of our Beijing facility continues to progress and the facility is near completion. We anticipate additional capacity for growth and significant efficiency improvements once we move into the new building by the end of the year."
Mr. Liu continued, "Lotus has a well-established nationwide sales and distribution network, and strong product development capabilities. With the completion of our new headquarters, we believe we are well positioned with respect to the ongoing consolidation of the Chinese pharmaceutical industry."
Third Quarter 2011 Results of Operations
Revenues
Revenues for the three months ended September 30, 2011 were $19.0 million as compared to $18.3 million for the three months ended September 30, 2010. The increase of $0.7 million, or 4.0%, was primarily due to the continued expansion of our OTC sales division. Wholesale revenue stayed roughly flat year-over-year at $15.3 million, or 80.2% of total revenues. Retail revenues increased 27.4% year-over-year to $3.8 million, or 19.8% of total revenues.
Gross Profit
Gross profit for the three months ended September 30, 2011 were $3.3 million as compared to $10.4 million for the three months ended September 30, 2010. Costs of sales for the three-month period were $15.7 million as compared to $7.9 million for the same period a year ago. The Company's gross margin was 17.4% and 56.7%, for the three months ended September 30, 2011 and 2010, respectively.
Income from Operations
Operating income for the three months ended September 30, 2011 amounted to $1.3 million as compared to $6.8 million for the three months ended September 30, 2010. Operating expenses for the three-month period totaled $2.0 million as compared to $3.6 million for the same period in 2010. The decrease in operating expenses was primarily due to the decrease in selling expenses and G&A expenses, partially offsetting by the increase in R&D expenses.
Net Income
Net income for the three months ended September 30, 2011 was $1.3 million as compared to $6.7 million for the three months ended September 30, 2010, due to the reasons set forth above. Earnings per diluted share were $0.04 for the quarter, compared with diluted EPS of $0.25 for the same period a year ago.
Liquidity and Capital Resources
As of September 30, 2011, the Company's current assets were $7.6 million and current liabilities were $14.2 million. Cash and cash equivalents totaled $0.2 million as of September 30, 2011. The Company's shareholders' equity at September 30, 2011 was $99.5 million. The Company generated $10.6 million in cash from operating activities for the nine months ended September 30, 2011, compared to $19.0 million for the same period in 2010. The Company used $11.8 million in net cash for investing activities for the nine months ended September 30, 2011, compared to $22.1 million for the same period in 2010.
Recent Business Highlights
Business Outlook for 2011
2011 is a transitional year for Lotus Pharmaceuticals, as the Company focuses its efforts on completing its new headquarters and shifting its focus to the wholesale business in Beijing and the surrounding areas. After the completion of the headquarters, the Company expects the growth of revenue and profitability will resume, driven primarily by the wholesale business in Beijing.
Conference Call and Webcast
Management will host a conference call to discuss these financial results on Monday, November 14, 2011 at 10:00 a.m. EST (7:00 a.m. PST).
To participate in the call, please dial (877) 941-4774, or (480) 629-9760 for international calls, approximately 10 minutes prior to the scheduled start time.
A replay of the call will be available for two weeks from 1:00 p.m. EST on November 14, 2011, until 11:59 p.m. EST on November 28, 2011. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4487388.
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. is a profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Information Regarding Forward-Looking Statements
Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.
Contacts:
Xing Shen, Ph.D.
VP of Corporate Development
Lotus Pharmaceuticals, Inc.
Ph: 415-690-7688
Email: shen@lotuspharma.com
Web: http://www.lotuspharma.com
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES | |||||||||
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME | |||||||||
(UNAUDITED) | |||||||||
For the Three Months Ended | For the Nine Months Ended | ||||||||
September 30, | September 30, | ||||||||
2011 | 2010 | 2011 | 2010 | ||||||
NET REVENUES: | |||||||||
Wholesale | $ 15,276,053 | $ 15,347,372 | $ 38,585,730 | $ 42,309,596 | |||||
Retail | 3,768,485 | 2,957,488 | 12,070,485 | 9,652,235 | |||||
Total Net Revenues | 19,044,538 | 18,304,860 | 50,656,215 | 51,961,831 | |||||
COST OF REVENUES: | |||||||||
Wholesale | 12,855,958 | 5,791,825 | 27,287,898 | 16,318,673 | |||||
Retail | 2,874,778 | 2,133,906 | 9,014,537 | 6,956,438 | |||||
Total Cost of Revenues | 15,730,736 | 7,925,731 | 36,302,435 | 23,275,111 | |||||
GROSS PROFIT | 3,313,802 | 10,379,129 | 14,353,780 | 28,686,720 | |||||
OPERATING EXPENSES: | |||||||||
Selling expenses | 846,919 | 2,452,629 | 2,987,630 | 6,996,741 | |||||
Research and development expenses | 470,311 | 21,517 | 1,889,535 | 21,517 | |||||
General and administrative expenses | 728,164 | 1,145,412 | 4,170,350 | 3,242,617 | |||||
Total Operating Expenses | 2,045,394 | 3,619,558 | 9,047,515 | 10,260,875 | |||||
INCOME FROM OPERATIONS | 1,268,408 | 6,759,571 | 5,306,265 | 18,425,845 | |||||
OTHER INCOME (EXPENSE): | |||||||||
Debt issuance costs | - | - | - | (52,226) | |||||
Other income | 47,717 | 200,074 | 141,331 | 597,016 | |||||
Interest income | 439 | 525 | 2,005 | 2,711 | |||||
Interest expense | (63,223) | (59,896) | (187,256) | (551,726) | |||||
Total Other Income (Expense) | (15,067) | 140,703 | (43,920) | (4,225) | |||||
INCOME BEFORE INCOME TAXES | 1,253,341 | 6,900,274 | 5,262,345 | 18,421,620 | |||||
INCOME TAXES | - | 200,348 | 149 | 470,514 | |||||
NET INCOME | 1,253,341 | 6,699,926 | 5,262,196 | 17,951,106 | |||||
OTHER COMPREHENSIVE INCOME: | |||||||||
Foreign currency translation gain | 930,264 | 1,426,434 | 3,054,039 | 1,760,632 | |||||
COMPREHENSIVE INCOME | 2,183,605 | 8,126,360 | $ 8,316,235 | $ 19,711,738 | |||||
NET INCOME PER COMMON SHARE: | |||||||||
Basic | $ 0.05 | $ 0.25 | $ 0.19 | $ 0.69 | |||||
Diluted | $ 0.04 | $ 0.25 | $ 0.19 | $ 0.67 | |||||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | |||||||||
Basic | 27,784,732 | 26,697,892 | 27,675,063 | 26,000,584 | |||||
Diluted | 28,094,644 | 27,047,556 | 27,985,245 | 26,872,434 | |||||
LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES | ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
(UNAUDITED) | ||||||
September 30, 2011 | December 31, 2010 | |||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash | $ 158,908 | $ 1,339,972 | ||||
Accounts receivable | 6,000,546 | 1,973,150 | ||||
Inventories | 1,268,875 | 634,583 | ||||
Prepaid expenses and other current assets | 128,805 | 593,759 | ||||
Total Current Assets | 7,557,134 | 4,541,464 | ||||
PROPERTY AND EQUIPMENT, net | 52,280,950 | 39,337,935 | ||||
OTHER ASSETS | ||||||
Land use right held for development or sale | 30,195,957 | 29,236,891 | ||||
Deposits and Installments on intangible assets | 9,840,982 | 9,528,419 | ||||
Land use rights, net | 13,111,904 | 12,932,421 | ||||
Other intangible assets, net | 7,169,988 | 7,607,485 | ||||
Total Assets | $ 120,156,915 | $ 103,184,615 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Accounts payable | $ 2,499 | $ 37,829 | ||||
Other payables and accrued liabilities | 723,557 | 3,441,466 | ||||
Taxes payable | 10,595,533 | 2,024,565 | ||||
Unearned revenue | 530,987 | 504,442 | ||||
Dividend payable | 5,743 | - | ||||
Due to related parties | 2,342,828 | 2,042,376 | ||||
Total Current Liabilities | 14,201,147 | 8,050,678 | ||||
LONG-TERM LIABILITIES: | ||||||
Due to related parties | 1,087,879 | 869,067 | ||||
Notes payable - related parties | 5,413,778 | 5,241,829 | ||||
Total Liabilities | 20,702,804 | 14,161,574 | ||||
COMMITMENTS AND CONTIGENCIES | ||||||
STOCKHOLDERS' EQUITY: | ||||||
Preferred stock ($.001 par value; 10,000,000 shares authorized; | ||||||
619,824 and 607,107 shares issued and outstanding | ||||||
at September 30, 2011 and December 31, 2010, respectively) | 620 | 607 | ||||
Common stock ($.001 par value; 100,000,000 shares authorized; | ||||||
27,800,927 and 26,763,485 shares issued and outstanding | ||||||
at September 30, 2011 and December 31, 2010, respectively) | 27,801 | 26,763 | ||||
Additional paid-in capital | 23,809,738 | 21,679,147 | ||||
Retained earnings | 59,170,490 | 53,925,101 | ||||
Statutory reserves | 6,240,202 | 6,240,202 | ||||
Accumulated other comprehensive income | 10,205,260 | 7,151,221 | ||||
Total stockholders' Equity | 99,454,111 | 89,023,041 | ||||
Total Liabilities and Stockholders' Equity | $ 120,156,915 | $ 103,184,615 | ||||
